JSF-3269 is a small molecule antibacterial inhibitor against Enterococcus faecium with MIC of 1.9-3.8 uM and minimal bactericidal concentration (MBC) of 7.7-15 uM.

JSF-3285 (JSF3285) is a potent small molecule inhibitor of the M. tuberculosis β-ketoacyl synthase KasA with Kd of 70.7 nM in MST assays, shows activity against H37Rv strain with MIC 0.2 uM.

KKL-55 is a specific small molecule inhibitor of bacterial trans-translation by binding to longation factor thermo-unstable (EF-Tu, Kd=2 uM), inhibits binding between EF-Tu and tmRNA but not between EF-Tu and tRNA, has broad-spectrum antibiotic activity.

KSK67 is a potent small molecule inhibitor of bacterial transcriptional activator PrfA with IC50 of 67 nM, reduces virulence factor expression in L. monocytogene.

LPC-233 (LPC233) is a highly potent and specific inhibitor of UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC (Ki=8.9 pM), specifically inhibits lipid A synthesis and displays outstanding antibiotic activities.

MD-124 is a potent antibiotic adjuvant against Gram-negative bacteria, sensitizes various Gram-negative bacterial species and strains, including multidrug resistant pathogens, toward existing antibiotics.

MMV1091186 (MMV 1091186) is an antimalarial compound that inhibit P. falciparum cytoplasmic isoleucyl tRNA synthetase (cIRS) with IC50 of 0.87 uM.

MMV652103 is an antimalarial imidazopyridazine compound, exerts potent and selective cytotoxicity in ER+ breast cancer cells, potently inhibits the oncogenic PI4KB and PIK3C2G lipid kinases with IC50 of 1.7 and 0.085 uM, respectively.

MSU-43085 is a potent, orally bioavailable inhibitor of Mycobacterium tuberculosis (Mtb, EC50=120 nM) and M. abscessus survival, targets MmpL3.

ND-011992 is a cytochrome bd oxidase (Cyt-bd) inhibitor, inhibits Mycobacterium tuberculosis respiratory complex I with IC50 of 0.12 uM, targets respiratory complex I and bo3 oxidase in addition to bd-I and bd-II oxidases.

NSC116565 is a potent, time-dependent inhibitor of Mycobacterium tuberculosis (M.tb) ketol-acid reductoisomerase (KARI) with Ki of 95.4 nM.

NTB-3119 (NTB3119) is a novel benzothiopyranone derivative and anti-tuberculosis agent with potent in vitro activity against both drug-susceptible and drug-resistant tuberculosis clinical strains.

OTB-658 (OTB658) is a novel oxazolidinone anti-tuberculosis agent, shows potent antibacterial activity against Mycobacterium tuberculosis, especially multi-drug resistant tuberculosis (MDR-TB) in vitro and in vivo.

PKZ18-22 is a potency improved analog of PKZ18, inhibitiong tRNA-regulated gene expression of gram-positive bacteria, shows MIC value of 8 ug/mL against S. aureus.

SAV13 is a selective small molecule inhibitor of S. aureus exoprotein expression regulator (SaeR) withEC50 of 1.06 uM in luciferase assays, reduces expression of hla and other virulence factors.

Savirin (S. aureus virulence inhibitor) is a small molecule inhibitor inhibiting agr quorum sensing in S. aureus by blocking the transcriptional function of AgrA.

SF235 is a small-molecule inhibitor of macrophage infectivity potentiator (Mip) protein with IC50 and Ki 0.42 and 0.29 uM against B. pseudomallei Mip (BpMip) peptidyl-prolyl cis/trans isomerase (PPIase) activity, reduce B. pseudomallei virulence in vitro.

SK-017154-O is a specific and noncompetitive inhibitor of PelA, specifically inhibits PelA esterase activity with IC50 of 11 uM, inhibits Pel-dependent PA14 biofilms with IC50 of 1.8 uM.

SMARt751 is a small molecule that interacts with the transcriptional regulator VirS of M. tuberculosis, up-regulates expression of the mymA operon, reverses resistance to ethionamide both in vitro and in vivo.

SMT-738 is a small-molecule inhibitor of bacterial lipoprotein transport complex (LolCDE), shows potent and highly selective antimicrobial activity.

TBAJ-5307 is a broad spectrum anti-non-tuberculous mycobacteria (NTM) inhibitor targeting FO-domain of F1FO-ATP synthase, shows MIC50 of 4.5 nM and 6 nM against the Mab subsp. abscessus smooth strain and rough strain respectively.

TBI-166 is a potential next-generation antituberculosis riminophenazine with activity against Mycobacterium tuberculosis (0.063  μg/ml).